Login to Your Account



Deals And M&A NEWS
HONG KONG – Newly listed Chinese biopharmaceutical company Shenyang-based 3SBio Inc. acquired small-molecule maker Zhejiang Wansheng Pharmaceutical Co. Ltd. for ¥528 million (US$85 million) to complement its oncology and nephrology pipeline.

SHANGHAI – Phagelux Inc., a Shanghai-based company developing bacteriophages for both human and animal use, has acquired Omnilytics Inc. 

Fibrocell Science Inc. and Intrexon Corp. took their partnership to the next level with the submission of an IND application with the FDA for FCX-007.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: